We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+1.97%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$263M
AUM Growth
-$18.5M
Cap. Flow
-$22.4M
Cap. Flow %
-8.53%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$14M
2
XLRN
Acceleron Pharma
XLRN
+$7.9M
3
EPZM
Epizyme, Inc
EPZM
+$559K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.87B
$261M 99.34%
1,753,528
– –
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$1.73M 0.66%
690,002
-142,334
-17% -$559K
NVAX icon
3
Novavax
NVAX
$1.23B
– –
-67,373
Closed -$14M
XLRN
4
DELISTED
Acceleron Pharma
XLRN
– –
-45,884
Closed -$7.9M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q4 2021 Portfolio in Review

As of Q4 2021, Foresite Capital Management II held 4 positions worth $263M, down 6.6% from $281M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II withdrew a net $22.4M in Q4 2021, closing 2 positions and reducing 1 holding. Its most notable exit was Novavax, an estimated $14M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management II's biggest Q4 2021 reduction was Epizyme, Inc, cutting an estimated $559K.
  • Foresite Capital Management II fully exited Novavax in Q4 2021, selling an estimated $14M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $263M portfolio in Q4 2021.
  • Foresite Capital Management II opened 0 new positions and closed 2 in Q4 2021.
  • Foresite Capital Management II's portfolio value fell 6.6% quarter-over-quarter to $263M.

Based on Foresite Capital Management II's 13F filing for Q4 2021, filed 11 Feb 2022.